Surgical Oncology Training Grant

肿瘤外科培训补助金

基本信息

项目摘要

The Department of Surgery at the University of California, San Francisco is one of the leading surgical departments in the world and has a rich history of scientific, educational, and clinical advancements. We are proposing an innovative new training program to encourage surgical residents to pursue clinician-scientist careers in surgical oncology and position them for leadership roles in the field. The practice of cancer care has changed considerably over the last 5 years with the introduction of a plethora of targeted agents and new technologies. Now, more than ever, surgical oncologists are required to have a broad understanding of the biological bases of cancer and its treatment, as well as training in modern clinical and translational methodologies. To be leaders in the field and make real improvements in cancer care, however, they must also be able to confidently navigate both the regulatory processes and the complex healthcare delivery environment in which we work. This program will be the first on the West Coast to explicitly support surgical residents in oncology research. It will also be the only T32 that explicitly incorporates training in regulatory research and innovation, integrating this with translational/clinical sciences and health services/implementation science. The core of this training program are mentored research projects, which will focus on one of the three themes, but with the guidance of faculty mentors, will include aspects of all three themes. Among the unique opportunities presented in this program is the option for short-term placement at the FDA to address problems in regulatory science. Another important aspect of the program is a series of courses and workshops designed to develop the leadership skills necessary to evoke positive change, guide productive research projects and teams and create a diverse and inclusive work environment. We will initially fund two positions each year for two years, which will be available to third year surgery residents undertaking their research elective. An external advisory board of leaders in oncology, trials, implementation science and education will advise the program. The program is led by Dr. Laura Esserman, who has demonstrated her commitment to training throughout her career, and who has the full and conscientious support of the department and institution for this program. The rich research environment of UCSF Department of Surgery, the carefully selected faculty mentors and the availability of numerous large-scale research programs provides ample opportunity for meaningful mentored research projects that will provide strong foundations for trainees future careers as clinician-scientists.
加州大学旧金山分校的外科系是领先的外科系之一 科室在世界各地都有,并在科学、教育和临床进步方面拥有丰富的历史。我们是 提出一项创新的培训计划,鼓励外科住院医师追求临床医生科学家 肿瘤外科的职业生涯,并将他们定位为该领域的领导角色。癌症护理实践已 随着大量靶向药物和新药物的引入,过去 5 年发生了很大变化 技术。现在,外科肿瘤学家比以往任何时候都更需要对肿瘤有广泛的了解。 癌症及其治疗的生物学基础,以及现代临床和转化培训 方法论。然而,要成为该领域的领导者并真正改善癌症护理,他们还必须 能够自信地应对监管流程和复杂的医疗保健服务环境 我们工作的地方。 该计划将是西海岸第一个明确支持外科住院医师进行肿瘤学研究的计划。它 也将是唯一一个明确纳入监管研究和创新培训的 T32, 这与转化/临床科学和卫生服务/实施科学有关。本次培训的核心 计划是指导性研究项目,将重点关注三个主题之一,但在 教师导师将包括所有三个主题的各个方面。在本次会议中提供的独特机会中 计划是在 FDA 短期安置的选择,以解决监管科学中的问题。其他 该计划的一个重要方面是一系列旨在培养领导技能的课程和研讨会 必要的激发积极的变化,指导富有成效的研究项目和团队,并创建一个多样化和 包容性的工作环境。我们最初将每年资助两个职位,为期两年,可供 第三年的外科住院医师正在进行选修研究。由领导者组成的外部顾问委员会 肿瘤学、试验、实施科学和教育将为该计划提供建议。 该计划由 Laura Esserman 博士领导,她自始至终都表现出了对培训的承诺。 事业,并得到了部门和机构对这个项目的全力和认真的支持。这 UCSF外科系丰富的研究环境、精心挑选的师资导师以及 许多大型研究项目的可用性为有意义的指导提供了充足的机会 研究项目将为学员未来作为临床医生科学家的职业生涯奠定坚实的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LAURA J ESSERMAN其他文献

LAURA J ESSERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LAURA J ESSERMAN', 18)}}的其他基金

Surgical Oncology Training Grant
肿瘤外科培训补助金
  • 批准号:
    10434765
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
  • 批准号:
    10368970
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
  • 批准号:
    9888251
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Surgical Oncology Training Grant
肿瘤外科培训补助金
  • 批准号:
    10683105
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
  • 批准号:
    10593908
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Surgical Oncology Training Grant
肿瘤外科培训补助金
  • 批准号:
    10025197
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Enhancing the Diversity of Participants in the WISDOM Clinical Trial: Practical Challenges and Ethical Implications
增强 WISDOM 临床试验参与者的多样性:实际挑战和伦理影响
  • 批准号:
    10367828
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
Extending the Diversity, Reach, and Generalizability of the WISDOM Study
扩展 WISDOM 研究的多样性、范围和普遍性
  • 批准号:
    10593908
  • 财政年份:
    2020
  • 资助金额:
    $ 33.14万
  • 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
  • 批准号:
    9360068
  • 财政年份:
    2017
  • 资助金额:
    $ 33.14万
  • 项目类别:
I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
I-SPY2:改进 I-SPY 2 试验,纳入 MRI 引导的适应性序贯治疗,以优化乳腺癌结果
  • 批准号:
    10249153
  • 财政年份:
    2017
  • 资助金额:
    $ 33.14万
  • 项目类别:

相似海外基金

K12 Training for Clinical and Translational Oncology Researchers
临床和转化肿瘤学研究人员的 K12 培训
  • 批准号:
    10647170
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
开发和自动化基于细胞外囊泡的测试以早期检测肝细胞癌
  • 批准号:
    10823687
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Novel Mechanisms in the Resolution of Post-Surgical Lymphedema
解决术后淋巴水肿的新机制
  • 批准号:
    10580412
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
Diversity Supplement: Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer
多样性补充:局部晚期直肠癌全新辅助治疗期间有氧训练的剂量反应
  • 批准号:
    10817969
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
StARR Program in Cross-Disciplinary Oncology Clinician-Scientist Training
StARR 跨学科肿瘤学临床医生-科学家培训计划
  • 批准号:
    10592756
  • 财政年份:
    2023
  • 资助金额:
    $ 33.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了